Current Report Articles
FDA Approves EUA for Remdesivir
FDALogo (May 8, 2020) – On May 1, in a letter to Gilead, the Food and Drug Administration issued an emergency use authorization of remdesivir for the treatment of hospitalized 2019 coronavirus disease patients. Remdesivir, a direct acting antiviral drug that inhibits viral RNA synthesis, is an investigational drug administered by intravenous infusion and is not currently approved for any indication. For more information, including the scope of authorization, see the FDA remdesivir EUA letter; and the Fact Sheet for Healthcare Providers on the EUA of remdesivir. Information for patients and caregivers is included in a Fact Sheet for Patients and Parent/Caregivers.
--Karen Braman